John Flax, M.D. - President
Herbert Y. Meltzer, M.D. - Medical Director
Ronald A. Flax - Chief Operating Office
John Flax, M.D. - President
Prior to joining PrecisionMed, Inc. as its President and founder, Dr.
Flax worked in the pharmaceutical industry in both the United States and
United Kingdom. Dr. Flax has 15 years experience in clinical drug development
as director of cardiovascular development at Pfizer, Warner Lambert and
Beecham (UK). His experience includes designing and managing clinical
research programs as well as extensive FDA experience including prosecuting
new drug applications. Dr. Flax, while maintaining his position at PrecisionMed,
has consulted for numerous US and European pharmaceutical companies and
has represented them at FDA. Apart from the development of FDA submissions
and regular FDA interactions, Dr. Flax has conducted several successful
FDA Advisory committee meetings. Dr. Flax was trained in cardiology at
St. Mary's Hospital in London, UK, and holds a MB, ChB from the University
of Cape Town, South Africa and membership of the Royal College of Physicians
of the United Kingdom {MRCP (UK)}.
Herbert Y. Meltzer, M.D. - Medical Director
Dr. Meltzer received his B.A. from Cornell University in 1958, an M.A.
in Chemistry from Harvard University in 1959, and his M.D. from Yale University
School of Medicine in 1963. Dr. Meltzer received his psychiatric training
at the Massachusetts Mental Health Center. Dr. Meltzer has been professor
of psychiatry at the University of Chicago and Case Western Reserve University
School of Medicine. Dr. Meltzer is currently Bixler Professor of Psychiatry
and Pharmacology and Director of the Division of Psychopharmacology at
the Vanderbilt University School of Medicine. Dr. Meltzer is recipient
of the Daniel Efron Research Award of the ACNP, recently served as editor
of Psychopharmacology: The Third Generation of Progress, co-editor of
Neuropsychopharmacology, and past president of that group. Dr. Meltzer
is director of the research grant review program for the National Alliance
for Research in Schizophrenia and Depression (NARSAD). He has received
the Noyes Prize of the Commonwealth of Pennsylvania, the Edward J. Sachar
Award from Columbia University, the Lieber Prize from NARSAD, and the
Stanley Dean Award of the American College of Psychiatry for his research
on schizophrenia and the Gold Medal Award of the Society of Biological
Psychiatry. Dr. Meltzer is on the editorial board of the Archives of General
Psychiatry and 7 other scientific journals. Dr. Meltzer's major research
interests are the psychopharmacologic treatment of schizophrenia, the
neurochemistry of schizophrenia, the mechanism of action of new antipsychotic
drugs, pharmacoeconomics, and cognitive studies in schizophrenia.
Ronald A. Flax - Chief Operating Officer
Mr. Flax is Chief Operating Officer of PrecisionMed, Inc. Over the past
20 years he has held senior and executive level positions in major European
corporations in Operations, Human Resources and Legal Services. For 9
years, he was a Senior Vice-President of a publicly traded British retailer
where he was responsible for Worldwide Operations, Human Resources and
Labor Law matters. He was previously, for 7 years, General Counsel and
Head of Human Resources for a London based office equipment manufacturer
and distributor. Mr. Flax is a Law Graduate of the University of Cape
Town and formerly practiced as an Attorney of the Supreme Court of South
Africa, specializing in corporate transactions and labor law.
